CD274 and neoplasm: Nuclear PD-L1 accelerates tumorigenesis, confers resistance towards anti-PD1/PD-L1 therapies, and regulates cancer immune evasion and immunotherapy in the tumor microenvironment (Gao et al., 2020; Xiong et al., 2021; Yu et al., 2023).